Yan Leyfman
Apr 1, 2025, 12:48
Yan Leyfman: Dual-Targeted CAR-T Therapy Shows 100% Response in MCL
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Nirav N. Shah, et al. on LinkedIn:
“Dual-Targeted CAR T Therapy Shows 100% Response in Relapsed Mantle Cell Lymphoma (MCL).
A new phase I/II trial (NCT04186520) tested dual-targeted CD20/CD19 CAR T cells (LV20.19) in relapsed/refractory (R/R) MCL, showing promising efficacy and safety!
Key Findings:
- 100% overall response rate (88% complete response).
- Few relapses, with median follow-up of 15.8 months.
- Favourable safety: 94% had mild/moderate cytokine release syndrome, 18% had manageable neurotoxicity.
- Fast manufacturing: Most patients received CAR T cells within 8 days of apheresis.
This study highlights on-site adaptive CAR T manufacturing as a safe, efficient, and highly effective approach for MCL. Future research will determine long-term durability!
Click here for Manuscript.”
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Authors: Nirav N. Shah, et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51